Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro<sup>®</sup> tablets 1.25 mg, 2.5 mg, 5 mg)

DOI Web Site Web Site PubMed 30 References Open Access
  • Yamakawa Satoru
    Clinical Development Department III, Daiichi Sankyo Co., Ltd.
  • Homma Tsuyoshi
    Global Project Management Department, Daiichi Sankyo Co., Ltd.
  • Yamada Makiko
    Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
  • Igawa Yoshiyuki
    Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd.
  • Yoshimura Motonobu
    Translational Medicine Function, R & D Division, Daiichi Sankyo Co., Ltd.

Bibliographic Information

Other Title
  • エサキセレノン（ミネブロ<sup>®</sup>錠1.25 mg・2.5 mg・5 mg）の薬理学的特徴及び臨床試験成績
  • 新薬紹介総説 エサキセレノン(ミネブロ錠1.25mg・2.5mg・5mg)の薬理学的特徴及び臨床試験成績
  • シンヤク ショウカイ ソウセツ エサキセレノン(ミネブロジョウ 1.25mg ・ 2.5mg ・ 5mg)ノ ヤクリガクテキ トクチョウ オヨビ リンショウ シケン セイセキ

Search this article

Description

<p>Esaxerenone is a novel non-steroidal mineralocorticoid receptor antagonisit (MR blocker), whose unique binding to the MR-ligand domain yields a stronger MR antagonistic effect and higher selectivity than existing MR antagonisits. Esaxerenone was approved for the treatment of hypertension in Japan in January 2019. Esaxerenone suppresses the reduction of urinary Na+/K+ ratio in adrenalectomized rats and blood pressure increase, proteinuria, and renal tissue lesions in salt-sensitive hypertensive rats—all in a dose-dependent manner. Esaxerenone is rapidly absorbed and reaches intracellular targets because of its high membrane permeability, exhibits high bioavailability with small interindividual exposure variation, and is metabolized via several pathways (e.g., oxidation, glucuronidation, and hydrolysis), which is associated with low drug–drug interaction risk. As esaxerenone is slightly excreted into urine, its exposure is similar between elderly and non-elderly patients, and between patients with normal and moderately deteriorated renal function. Given its 19-hour half-life, once-daily administration would have a sustainable antihypertensive effect. The ESAX-HTN phase 3 study demonstrated the non-inferiority of esaxerenone’s antihypertensive effect versus that of eplerenone in essential hypertension. Another study showed a stable antihypertensive effect for 52 weeks as monotherapy or combination therapy. In hypertensive patients with moderate impairment or both type 2 diabetes and albuminuria treated with a renin–angiotensin system inhibitor, esaxerenone elicited a stable antihypertensive effect and manageable hyperkalemia incidence with titration from a low dose and monitoring including serum potassium. Thus, with careful monitoring of serum potassium, esaxerenone can be administered to patients with moderate renal impairment or both diabetes and albuminuria.</p>

Journal

References(30)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top